FRα-Targeted Antibody-Drug Conjugates With Cleavable Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates (ADCs) face challenges with high toxicity and limited therapeutic window, particularly when targeting folate receptor alpha (FRα), necessitating the development of ADCs with high specificity, low toxicity, and a differentiated mechanism of action.
Innovation Solution
The development of antibody-drug conjugates comprising a specific anti-FRα antibody linked to a topoisomerase I inhibitor, such as exatecan, through a cleavable linker that ensures targeted drug release, using modified IgG1 or IgG4 isotypes with reduced ADCC activity and protease-sensitive linkers for enhanced specificity and reduced systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If ADCs use highly potent cytotoxic drugs as payloads, then therapeutic efficiency is improved, but systemic toxicity increases
Solution Approach 1:
The ADC system segments the cytotoxic drug delivery into two distinct phases: (1) stable circulation phase where the drug-antibody conjugate remains intact in the bloodstream, and (2) release phase where the drug is liberated inside target cells. The cleavable linker acts as a temporal and spatial separator, preventing premature drug release and systemic toxicity while enabling potent localized action at the tumor site.
Solution Approach 2:
The cleavable linker serves as an intermediary component between the antibody and cytotoxic payload. It mediates the transition from stable conjugate to active drug, using enzymatic cleavage by tumor-associated proteases (such as cathepsins) to trigger drug release specifically within the tumor microenvironment, thereby protecting systemic circulation from drug exposure.
2Reliability
If ADCs use stable linkers to maintain conjugate integrity, then specificity is improved, but drug release efficiency decreases
Solution Approach 1:
The linker transitions from a stable state during circulation to a dynamic, cleavable state upon encountering tumor-specific proteases. This dynamic property allows the linker to maintain conjugate integrity in the bloodstream while enabling efficient drug release within the tumor, responding to the local enzymatic environment to switch between stability and lability.
Solution Approach 2:
The chemical parameters of the linker change in response to the tumor microenvironment. The linker is designed with specific peptide sequences or chemical bonds that are stable under physiological conditions but become susceptible to cleavage in the presence of tumor-associated proteases, altering its stability parameter from high (in circulation) to low (in tumor tissue) to control drug release timing and location.
3Ease of manufacture
If ADCs use non-specific linkers, then ease of manufacture is improved, but target-specificity decreases
Solution Approach 1:
The patent replaces mechanical or chemical stabilization methods with a biologically-responsive cleavage mechanism. Instead of using stable, non-cleavable linkers that rely on physical integrity, the system uses protease-sensitive peptide sequences that are naturally recognized and cleaved by tumor-associated enzymes, substituting enzymatic recognition for mechanical stability to achieve target-specificity.
4Adaptability or versatility
If ADCs broaden payload mechanisms of action, then adaptability to resistant tumors is improved, but complexity of ADC design increases
Solution Approach 1:
The patent applies multi-functionality by using a universal cleavable linker platform that can be conjugated to different cytotoxic payloads with diverse mechanisms of action (microtubule inhibitors, DNA alkylators, topoisomerase inhibitors). This universal linker design maintains consistent stability and cleavage properties across different drug-antibody combinations, enabling adaptability to various tumor types and resistance mechanisms without redesigning the entire ADC architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ADCs demonstrate excellent in vivo efficacy in solid tumor cancer models with low toxicity, outperforming reference ADCs by providing targeted drug delivery and improved therapeutic index.
Implementation Method 1
susceptible to cleavage by proteases, such as proteases preferentially expressed in tumor tissue, for example cathepsins (e.g. cathepsins B, C, D)
Implementation Method 2
susceptible to cleavage by low pH within the lysosomal compartment
Implementation Method 3
the antibody specifically binds to folate receptor alpha (FRα)
Implementation Method 4
the drug is preferably chosen among inhibitors of topoisomerase I, for example camptothecine analogues such as exatecan
Data Source
AI summary
The present invention relates to antibody-drug conjugates, wherein the antibody specifically binds to folate receptor a, and wherein the drug is preferably chosen among a cytotoxic drug. Such antibody-drug conjugates are useful in particular in treating proliferative diseases including cancers, such as ovarian, breast and non-small cell lung cancers.